JP2025506473A5 - - Google Patents

Info

Publication number
JP2025506473A5
JP2025506473A5 JP2024547305A JP2024547305A JP2025506473A5 JP 2025506473 A5 JP2025506473 A5 JP 2025506473A5 JP 2024547305 A JP2024547305 A JP 2024547305A JP 2024547305 A JP2024547305 A JP 2024547305A JP 2025506473 A5 JP2025506473 A5 JP 2025506473A5
Authority
JP
Japan
Prior art keywords
alkyl
cycloalkyl
group
substituted
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024547305A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025506473A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/074936 external-priority patent/WO2023151574A1/en
Publication of JP2025506473A publication Critical patent/JP2025506473A/ja
Publication of JP2025506473A5 publication Critical patent/JP2025506473A5/ja
Pending legal-status Critical Current

Links

JP2024547305A 2022-02-09 2023-02-08 ヘテロ環glp-1アゴニスト Pending JP2025506473A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2022075604 2022-02-09
CNPCT/CN2022/075604 2022-02-09
PCT/CN2023/074936 WO2023151574A1 (en) 2022-02-09 2023-02-08 Heterocyclic glp-1 agonists

Publications (2)

Publication Number Publication Date
JP2025506473A JP2025506473A (ja) 2025-03-11
JP2025506473A5 true JP2025506473A5 (cg-RX-API-DMAC10.html) 2026-02-17

Family

ID=87563618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024547305A Pending JP2025506473A (ja) 2022-02-09 2023-02-08 ヘテロ環glp-1アゴニスト

Country Status (5)

Country Link
US (1) US20250177362A1 (cg-RX-API-DMAC10.html)
EP (1) EP4476216A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025506473A (cg-RX-API-DMAC10.html)
CN (1) CN119343343A (cg-RX-API-DMAC10.html)
WO (1) WO2023151574A1 (cg-RX-API-DMAC10.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021219019A1 (en) 2020-04-29 2021-11-04 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
PE20231181A1 (es) 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
SI4408840T1 (sl) 2021-09-27 2025-12-31 Terns Pharmaceuticals, Inc. Benzimidazolne karboksilne kisline kot agonisti GLP-1R
US12024507B2 (en) 2021-10-25 2024-07-02 Terns Pharmaceuticals, Inc. Compounds as GLP-1R agonists
JP2025506474A (ja) * 2022-02-09 2025-03-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト
AU2023224854A1 (en) 2022-02-23 2024-10-03 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
PE20252787A1 (es) 2023-04-07 2025-12-22 Terns Pharmaceuticals Inc Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica
EP4777197A2 (en) 2023-09-14 2026-07-22 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025109387A1 (en) 2023-11-24 2025-05-30 Ascletis Pharma (China) Co., Limited Glp-1r agonist and therapeutic method thereof
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
WO2025222000A1 (en) * 2024-04-19 2025-10-23 Eli Lilly And Company Substituted 1,1'-biphenyl compounds as glucagon receptor agonists
TW202606664A (zh) * 2024-04-19 2026-02-16 美商美國禮來大藥廠 升糖素受體促效劑及其作為療法之用途
WO2026078617A1 (en) * 2024-10-11 2026-04-16 Pfizer Inc. Glucose-dependent insulinotropic polypeptide receptor antagonists and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190060A1 (ar) * 2016-09-26 2019-03-26 Chugai Pharmaceutical Co Ltd مشتق بيرازولو بيريدين له تأثير مساعد لمستقبل glp-1
WO2018109607A1 (en) * 2016-12-16 2018-06-21 Pfizer Inc. Glp-1 receptor agonists and uses thereof
CA3045644C (en) * 2018-06-13 2024-01-16 Pfizer Inc. Glp-1 receptor agonists and uses thereof
PE20231181A1 (es) * 2020-08-06 2023-08-11 Gasherbrum Bio Inc Agonistas del glp-1 heterociclicos
JP2025506474A (ja) * 2022-02-09 2025-03-11 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環glp-1アゴニスト

Similar Documents

Publication Publication Date Title
JP2023546055A5 (cg-RX-API-DMAC10.html)
JP2023537501A5 (cg-RX-API-DMAC10.html)
JP2023546054A5 (cg-RX-API-DMAC10.html)
JP2023515404A5 (cg-RX-API-DMAC10.html)
JP2025506474A5 (cg-RX-API-DMAC10.html)
JP2023538949A5 (cg-RX-API-DMAC10.html)
JP2025513071A5 (cg-RX-API-DMAC10.html)
JP2023540558A5 (cg-RX-API-DMAC10.html)
JP2023540609A5 (cg-RX-API-DMAC10.html)
DE69622532T2 (de) Glycoprotein iib/iiia-antagonisten
JP2023513272A5 (cg-RX-API-DMAC10.html)
JP2025509281A5 (cg-RX-API-DMAC10.html)
JP2025510741A5 (cg-RX-API-DMAC10.html)
JP2025504508A5 (cg-RX-API-DMAC10.html)
BG108060A (bg) Ацилирани 6,7,8,9-тетрахидро-5н- бензоциклохептениламини и използването им като фармацевтични средства
TWI532731B (zh) 新穎噠嗪酮及吡啶酮化合物
TWI691475B (zh) Urat1抑制劑
ZA200500026B (en) 7,8,9,10-tetrahydro-6H-azepino, 6,7,8,9-tetrahydo-pyrido and 2,3-dihydro-2H-pyrroloÄ2,1-bÜ-quinazolinone derivatives.
TW200911756A (en) Novel compounds
CN102223797A (zh) 金刚烷基苯甲酰胺化合物
CN121985948A (zh) Glp-1r激动剂的制剂及其制备方法
CN107207483A (zh) α‑氨基‑β‑羧基粘康酸半醛脱羧酶抑制剂
JPWO2005115993A1 (ja) キナゾリン誘導体
EP4163277A1 (en) Novel pyrazole derivatives
AR050631A1 (es) Combinacion de compuestos organicos